TITLE

Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication

AUTHOR(S)
Cameron, H. A.; Waller, P. C.; Ramsay, L. E.
PUB. DATE
July 1987
SOURCE
Angiology;Jul1987, Vol. 38 Issue 7, p549
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months' treatment with ketanserin (mean dose 167 mg/day) there was no significant change in claudication time (mean change +12%, 95% CI -9 ; +33%) or total walking time (mean change -14%, 95% CI -47%; +19%). The confidence intervals show that ketanserin treatment is unlikely to be associated with clinically important improvement.
ACCESSION #
16359706

 

Related Articles

  • Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study. Norgren, L; Jawien, A; Mátyás, L; Rieger, H; Arita, K; The European MCI-9042 Study Group // Vascular Medicine;2006, Vol. 11 Issue 2, p75 

    This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent...

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

  • A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication. Castaño, Gladys; Más, Rosa; Roca, Juan; Fernández, Lilia; Illnait, José; Fernandez, Julio César; Selman, Eugenio // Angiology;Feb1999, Vol. 50 Issue 2, p123 

    This study was undertaken to evaluate the efficacy and tolerability of policosanol, a new cholesterol-lowering drug with concomitant antiplatelet effects, in patients with intermittent claudication. After a baseline period of 6 weeks, 62 patients were randomized to receive, under double-blind...

  • Improvement of Walking Distance in Patients with Intermittent Claudication by Chronic Local Therapy with Isosorbide Dinitrate Ointment. Testa, Roberto; Biagini, Andrea; Michelassi, Claudio; Emdin, Michele; Mazzei, Maria Giovanna; Carpeggiani, Clara; L'Abatte, Antonio // Angiology;Jan1988 Part 1, Vol. 39 Issue 1, p1 

    Isosorbide dinitrate ointment (100 mg tid) was directly applied to 30 male patients with stable, documented intermittent claudication on the areas where ischemic pain was experienced. The symptom-free distance walked (DWA) and the maximum distance reached (MDR) basally, after one, three, six,...

  • Propionyl-l-carnitine for intermittent claudication. Deckert, James // Journal of Family Practice;Jun1997, Vol. 44 Issue 6, p533 

    The article discusses research being done on the effect of propionyl-L-carnitine on the quality of life in intermittent claudication, with reference to a study by G. Brevetti, S. Perna, C. Sabba et al, which appeared in the 1997 issue of the "American Journal of Cardiology." Patients included...

  • Effects of Alpha-Lipoic Acid Supplementation in Peripheral Arterial Disease: A Pilot Study. Vincent, Heather K.; Bourguignon, Cheryl M.; Vincent, Kevin R.; Taylor, Ann G. // Journal of Alternative & Complementary Medicine;Jun2007, Vol. 13 Issue 5, p577 

    Objective: To examine whether 3 months of lipoic acid (LA) supplementation improved walking tolerance and delayed claudication pain onset in peripheral arterial disease (PAD). Design: Randomized, double-blind, controlled study. Setting: General Clinical Research Center. Subjects: Twenty-eight...

  • Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication. Mohler, Emile R; Gainer, John L; Whitten, Kim; Eraso, Luis H; Thanaporn, Porama Koy; Bauer, Timothy // Vascular Medicine;Oct2011, Vol. 16 Issue 5, p346 

    Trans sodium crocetinate (TSC) is a synthetic carotenoid that improves the diffusion of oxygen in animal models of ischemia/hypoxia. This study evaluated multiple doses of TSC in patients with peripheral artery disease (PAD) and hypothesized that a preliminary dose–response relationship...

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Methylprednisolone/sodium chloride.  // Reactions Weekly;11/29/2008, Issue 1230, p26 

    The article presents a case study of a 62-year-old man who had a reaction to the administration of methylprednisolone in saline solution. The patient reported leg pain and weakness after the first bolus. The condition returned to baseline after the therapy was discontinued. The condition...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics